{"disease":{"id":"cholangiocarcinoma-non-resectable","name":"cholangiocarcinoma non resectable"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06670547","title":"Spanish Registry of Quality Indicators and Adverse Events of Endoscopic Retrograde Cholangiopancreatography","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Germans Trias i Pujol Hospital","has_results":false},{"nct_id":"NCT07454486","title":"TRACE-BTC. Relation of Biomarkers and Patients Reported Quality of Life to Outcomes in Patients With Biliary Tract Cancer: a Real- World Cohort","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Aarhus University Hospital","has_results":false},{"nct_id":"NCT06671418","title":"Primary Percutaneous Stenting Above the Ampulla Versus Endoscopic Drainage for Unresectable Malignant Hilar Biliary Obstruction","phase":"PHASE3","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":148,"lead_sponsor_name":"Erasmus Medical Center","has_results":false},{"nct_id":"NCT03473574","title":"Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":128,"lead_sponsor_name":"AIO-Studien-gGmbH","has_results":false},{"nct_id":"NCT06194695","title":"DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Ze-yang Ding, MD","has_results":false},{"nct_id":"NCT03043547","title":"Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"AIO-Studien-gGmbH","has_results":false},{"nct_id":"NCT04860154","title":"Photodynamic Therapy for Cholangiocarcinoma","phase":"NA","overall_status":"COMPLETED","enrollment_count":86,"lead_sponsor_name":"Hepatopancreatobiliary Surgery Institute of Gansu Province","has_results":false},{"nct_id":"NCT03267940","title":"Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":85,"lead_sponsor_name":"Halozyme Therapeutics","has_results":true},{"nct_id":"NCT03377179","title":"A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"RedHill Biopharma Limited","has_results":false},{"nct_id":"NCT05978609","title":"Cadonilimab With Chemotherapy in Treating Advanced Biliary Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":65,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT02495896","title":"Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":61,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT06487663","title":"TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors","phase":"NA","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT03364530","title":"Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"University Hospital, Montpellier","has_results":false},{"nct_id":"NCT06192784","title":"Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":36,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT06192797","title":"Combined HAIC, Lenvatinib and Pucotenlimab As Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT07326189","title":"Preoperative Right Hepatic Artery Embolization for Locally Advanced Bismuth IIIb and IV Perihilar Cholangiocarcinoma","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":33,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT05655949","title":"Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Beth Israel Deaconess Medical Center","has_results":false},{"nct_id":"NCT06850753","title":"En Bloc Resection of the Liver and Pancreas With a \"Non-touch\" Technique Followed by Liver Transplantation to Improve the Overall Survival in Patients With Non-resectable Hilar Cholangiocarcinoma Beyond the Mayo Clinic Transplant Criteria","phase":"NA","overall_status":"RECRUITING","enrollment_count":15,"lead_sponsor_name":"Oslo University Hospital","has_results":false},{"nct_id":"NCT03414489","title":"Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®)","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"RedHill Biopharma Limited","has_results":false}],"total":19},"guidelines":[],"source":"Drug Landscape verified database"}